Plant Name: Ajania fruticulosa
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.028E-12 | 1.119E-08 | CA12, CA2, CA4, CA5B, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.707E-12 | 2.691E-08 | CA12, CA2, CA4, CA5B, CA7, CA9 |
| MF | GO:0005488; binding | GO:0046914; transition metal ion binding | 4.616E-07 | 1.256E-03 | CA12, CA2, CA4, CA5B, CA7, CA9, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.659E-06 | 3.613E-03 | CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.054E-06 | 5.115E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 4.179E-06 | 6.067E-03 | AKR1B1, ALDH1A1, CYP1B1, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 5.247E-06 | 6.645E-03 | CA2, CA9, CASP1, CASP7, CYP1A2, CYP1B1, NFKB1 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.104E-06 | 6.645E-03 | CYP1A2, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.676E-15 | 5.828E-11 | CA12, CA2, CA4, CA5B, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 5.365E-15 | 4.238E-13 | CA12; CA5B; CA2; CA4; CA7; CA9 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 2.170E-05 | 6.709E-04 | CASP7; CASP1; NFKB1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.548E-05 | 6.709E-04 | CYP1A2; CYP1B1; CYP3A4 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 3.590E-05 | 7.091E-04 | CYP1A2; ALDH1A1; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 5.086E-05 | 7.262E-04 | CYP1A2; CYP1B1; CYP3A4 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 5.515E-05 | 7.262E-04 | CASP7; CASP1; NFKB1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 7.201E-05 | 8.127E-04 | CYP1A2; CYP1B1; CYP3A4 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 5.975E-04 | 4.720E-03 | CASP7; MAPT; HSD17B10 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 7.243E-04 | 5.202E-03 | CYP1A2; CYP1B1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.795E-04 | 3.331E-03 | CYP1A2; CYP3A4 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.374E-04 | 2.344E-03 | CA2; CA4 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 1.467E-03 | 9.658E-03 | CASP1; NFKB1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.141E-03 | 1.193E-02 | CYP1A2; CYP3A4 |
| hsa04623 | Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | 1.845E-03 | 1.121E-02 | CASP1; NFKB1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 6.417E-03 | 2.668E-02 | CYP1A2; ALDH1A1; AKR1B1; CYP3A4; HSD17B10 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 2.265E-03 | 1.193E-02 | CA2; CYP3A4 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 5.339E-03 | 2.343E-02 | CASP7; NFKB1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 3.302E-03 | 1.630E-02 | CASP1; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 8.511E-03 | 3.362E-02 | CASP7; NFKB1 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 9.841E-03 | 3.702E-02 | CASP7; NFKB1 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.304E-02 | 4.683E-02 | CASP1; NFKB1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 4.991E-03 | 2.319E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; CA9 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1; AKR1B1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |